The effect of early resuscitation and ulinastatin on the severe acute pancreatitis in obese patients


Keywords: pancreatitis, obesity, ulinastatin.

Abstract

Annotation. Obesity is a problem of the third millennium. It is known that obesity is a major factor in the development of various diseases, including acute pancreatitis. Obesity itself is a pro-inflammatory condition with elevated levels of the following pro-inflammatory cytokines: tumor necrosis factor (TNF-a), interleukin (IL) IL-10, IL-6, IL-1b. Acute pancreatitis is also a disease based on the pathogenesis of the cytokine reaction and autolysis. Thus, against the background of the already formed inflammatory response, the inflammatory response intensifies and increases, and the level of pro-inflammatory cytokines reaches critical values. The purpose is to study the effect of ulinastatin on the severe acute pancreatitis in obese patients. To refute or confirm the hypothesis among patients with severe acute pancreatitis and obesity (BMI was 37.48±2.19 kg / m2), two groups were randomized. In the first group (experimental) of 18 patients, a step-up approach was performed. In the second group (control), the total number of which was 18 patients, a standard treatment algorithm was performed. The experimental group suggested the use of early resuscitation with Ringer’s lactate and ulinastatin in the first 5 days of the disease. The drug was administered at a dose of 200,000 IU by intravenous infusion for 1 hour 3 times a day for 5 days. In the control group, resuscitation was performed with 0.9% sodium chloride solution without the use of ulinastatin. Hypothesis was tested by monitoring procalciton and C-reactive protein, interleukin-1 and interleukin-6 over a period of 24 hours, 48 hours, 10 days, 15 days, 30 days, 45 and 60 days. The choice of procalcitonin and CRP was made by calculating the relative risk, as the level of CRP> 200mg / l indicated the preservation of severe disease (RR=2.07; 95% CI=1.65-2.59; p=0.01), and an increase in procalcitonin> 1.8 ng / mg was a predictor of infection (RR=2.27; 95% CI=1.083-4.769; p=0.02). The use of ulinastatin during the first 5 days in the experimental group reduced the level of interleukin-1 from 23.64±4.13 to 8.71±2.49 pg / ml (p=0.001; α=0.05), interleukin- 6 – from 29.72±4.27 to 12.43±2.36 pg / ml (p=0.001; α=0.05). The use of resuscitation with Ringer's lactate solution in combination with ulinastatin for 5 days helped to reduce the level of procalciton in 1.8 times (2.89±0.88 compared with 1.8±0.23 ng / mg; p=0.001; α=0.05). The level of CRP during the period of ulinastatin decreased by 41.68 (267.28±114.11 compared with 225.6±84.9 mg / l; p=0.01; α=0.05). In-hospital mortality was significantly lower in the ulinastatin group (16% vs. 69.6%; p=0.0003; α=0.05). Significantly lower proportion of patients (24% compared to 73.9%; p=0.0005; α=0.05) with multiple organ failure among the study group. Organ dysfunction was acquired on day 5 among patients taking ulinastatin. The length of hospital stay was 49.7±4.2 bed-days, while in the comparison group – 56.67±5.84 bed-days (p=0.01; α=0.05). Thus, the use of Ringer-lactate early resuscitation in combination with ulinastatin has improved the treatment of severe acute pancreatitis in obese patients.

References

1. Abraham, P., Rodriques, J., Moulick, N., Dharap, S., Chafekar, N., Verma, P. K., … & Bakshi, G. (2013). Efficacy and safety of intravenous ulinastatin versus placebo along with standard supportive care in subjects with mild or severe acute pancreatitis. J. Assoc. Physicians India, 61 (8), 535–538. Retrieved from https://pubmed.ncbi.nlm.nih.gov/24818336/

2. Afghani, E., Pandol, S. J., Shimosegawa, T., Sutton, R., Wu, B. U., Vege, S. S., … & Mayerle, J. (2015). Acute pancreatitis – progress and challenges: a report on an international symposium. Pancreas, 44 (8), 1195–210. doi: 10.1097/MPA.0000000000000500

3. Arlt, A., Erhart, W., Schafmayer, C., Held, H. C., & Hampe, J. (2014). Antibiosis of necrotizing pancreatitis. Visceral Medicine, 30 (5), 318–324. https://doi.org/10.1159/000367948

4. Banks, P. A., Bollen, T. L., Dervenis, C., Gooszen, H. G., Johnson, C. D., Sarr, M. G., … Vege, S. S. (2013). Classification of acute pancreatitis – 2012: revision of the Atlanta classification and definitions by international consensus. Gut, 62 (1), 102–111. doi: 10.1136/gutjnl-2012-302779

5. Bendersky, V. A., Mallipeddi, M. K., Perez, A., & Pappas, T. N. (2016). Necrotizing pancreatitis: challenges and solutions. Clin. Exp. Gastroenterol., 9, 345–350. doi: 10.2147/CEG.S99824

6. Bruno, M. J. (2016). Dutch Pancreatitis Study Group. Improving the outcome of acute pancreatitis. Dig. Dis., 34 (5), 540–545. doi: 10.1159/000445257

7. Chen, C. C., Wang, S. S., & Lee, F. Y. (2007). Action of antiproteases on the inflammatory response in acute pancreatitis. JOP, 8 (4), 488–494. Retrieved from https://pancreas.imedpub.com/action-of-antiproteases-on-the-inflammatory-response-in-acute-pancreatitis.php?aid=2593

8. Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., … & Moreno, R. (2013). Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med., 41 (2), 580–637. doi: 10.1097/CCM.0b013e31827e83af

9. Dumnicka, P., Maduzia, D., Ceranowicz, P., Olszanecki, R., Drożdż, R., Kuśnierz-Cabala, B. (2017). The interplay between inflammation, coagulation and endothelial injury in the early phase of acute pancreatitis: clinical implications. Int. J. Mol. Sci., 18 (2), 354. doi: 10.3390/ijms18020354

10. Freeman, M., Gardner, T., Mayerle, J., Vege, S. S., Werner, J., Banks, P., … & Zyromski, N. (2013). IAP/APA evidence-based guidelines for the management of acute pancreatitis. Pancreatology, 13 (4, 2), e1–15. doi: 10.1016/j.pan.2013.07.063

11. Fries, E., & Blom A. M. (2000). Bikunin – not just a plasma proteinase inhibitor. Int. J. Biochem. Cell Biol., 32 (2), 125–137. doi: 10.1016/s1357-2725(99)00125-9

12. Greenberg, J. A., Hsu, J., Bawazeer, M., Marshall, J., Friedrich, J. O., Nathens, A., … & McLeod, R. S. (2016). Clinical practice guideline: management of acute pancreatitis. Can J. Surg., 59 (2), 128–40. doi: 10.1503/cjs.015015

13. Hirano, T., & Manabe, T. (1993). Human urinary trypsin inhibitor, urinastatin, prevents pancreatic injuries induced by pancreaticobiliary duct obstruction with cerulein stimulation and systemic hypotension in the rat. Arch. Surg., 128 (12), 1322–1329. doi: 10.1001/archsurg.1993.01420240030004

14. Huan, C., Kim, D., Ou, P., Alfonso, A., & Stanek, A. (2016). Mechanisms of interleukin-22's beneficial effects in acute pancreatitis. World J. Gastrointest. Pathophysiol., 7 (1), 108–116. doi: 10.4291/wjgp.v7.i1.108

15. Janisch, N. H., & Gardner, T. B. (2016). Advances in management of acute pancreatitis. Gastroenterol. Clin. North Am., 45 (1), 1–8. doi: 10.1016/j.gtc.2015.10.004

16. Johnson, C. D., & Abu-Hilal, M. (2004). Persistent organ failure during the first week as a marker of fatal outcome in acute pancreatitis. Gut, 53 (9), 1340–1344. doi: 10.1136/gut.2004.039883

17. Kebkalo, A., Tkachuk, O., & Reyti, A. (2019). Features of the course of acute pancreatitis in patients with obesity. Pol. Przegl. Chir, 91 (6), 28–34. doi: 10.5604/01.3001.0013.4147

18. Kebkalo, A., Tkachuk, O., & Reiti, A. (2019). Peculiarities of Clinical Indices, Duration and Complication of Acute Pancreatitis in Patients with Comorbid Obesity. ISSN 2306-4269. Lviv Сlinical Bulletin., 2 (26)–3(27), 16–23. DOI: 10.25040/lkv2019.02.016

19. Kitagawa, M., & Hayakawa, T. (2007). Antiproteases in the treatment of acute pancreatitis. JOP, 8 (4), 518–525. Retrieved from https://pubmed.ncbi.nlm.nih.gov/17625309/

20. Linder, A., & Russell, J. A. (2014). An exciting candidate therapy for sepsis: ulinastatin, a urinary protease inhibitor. Intensive Care Med., 40 (8), 1164–1167. doi: 10.1007/s00134-014-3366-9

21. Maciejewski, R., Burdan, F., Burski, K., Madej, B., Ziemiakowicz, R., Dąbrowski, A., & Wallner, G. (2005). Selected biochemical parameters and ultrastructural picture of pancreas due to ulinastatin treatment of experimental acute pancreatitis. Exp. Toxicol. Pathol., 56 (4), 305–311. doi: 10.1016/j.etp.2004.09.001

22. Meher, S., Mishra, T. S., Sasmal, P. K., Rath, S., Sharma, R., Rout, B., … & Sahu, M. K. (2015). Role of biomarkers in diagnosis and prognostic evaluation of acute pancreatitis. J. Biomarkers, 2015, 519534. doi: 10.1155/2015/519534

23. Pandol, S. J., Saluja, A. K., Imrie, C. W., & Banks, P. A. (2007). Review in basic and clinical gastroenterology. Gastroenterology, 132, 1127–1151. doi:10.1053/j.gastro.2007.01.055

24. Schouten, M., Wiersinga, W. J., Levi, M., & Van Der Poll, T. (2008). Inflammation, endothelium, and coagulation in sepsis. J. Leukoc. Biol., 83 (3), 536–545. doi: 10.1189/jlb.0607373

25. Srinivasan, G., Venkatakrishnan, L., Sambandam, S., Singh, G., Kaur, M., Janarthan, K., … & John, J. (2016). Current concepts in the management of acute pancreatitis. J. Family Med. Prim. Care, 5 (4), 752–758. DOI: 10.4103/2249-4863.201144

26. Surati, K., Suthar, K., Shah, J., & Parekh, B. (2014). A study of recent trends in acute pancreatitis. Int. J. Med. Sci. Public. Health, 3 (1), 63–68. DOI: 10.5455/ijmsph.2013.011020131

27. Tani, S., Otsuki, M., Itoh, H., Nakamura, T., Fujii, M., Okabayashi, Y., … & Baba, S. (1988). The protective effect of the trypsin inhibitor urinastatin on cerulein-induced acute pancreatitis in rats. Pancreas, 3 (4), 471–476. doi: 10.1097/00006676-198808000-00017

28. Umeadi, C., Kandeel, F., & Al-Abdullah, I. H. (2008). Ulinastatin is a novel protease inhibitor and neutral protease activator. Transplantation Proceedings, 40 (2), 387–389. doi: 10.1016/j.transproceed.2008.01.034

29. Wallner, G., Solecki, M., Ziemiakowicz, R., Ćwik, G., Dyndor, P., & Maciejewski, R. (2013). Morphological changes of the pancreas in course of acute pancreatitis during treatment with ulinastatin. Pol. Przegl. Chir., 85 (3), 114–122. DOI: 10.2478/pjs-2013-0020

30. Yang, Z. W., Meng, X. X., & Xu, P. (2015). Central role of neutrophil in the pathogenesis of severe acute pancreatitis. J. Cell Mol. Med., 19 (11), 2513–2520. doi: 10.1111/jcmm.12639

31. Zhang, C., Wang, Y., Fu, W., Zhang, W., Wang, T., & Qin, H. (2016). A meta-analysis on the effect of ulinastatin on serum levels of C-reactive protein, interleukin 6, and tumor necrosis factor alpha in Asian patients with acute pancreatitis. Genet. Test Mol. Biomarkers, 20 (3), 118–124. doi: 10.1089/gtmb.2015.0192
Published
2020-10-12
How to Cite
Tkachuk, O., & Kebkalo, A. (2020). The effect of early resuscitation and ulinastatin on the severe acute pancreatitis in obese patients. Reports of Vinnytsia National Medical University, 24(3), 449-454. https://doi.org/https://doi.org/10.31393/reports-vnmedical-2020-24(3)-13